Approval · Notice of Compliance 266 · 2003
CAVERJECT: Notice of Compliance 266
Issued September 16, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 266
- Date
- September 16, 2003
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Prostaglandin
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CAVERJECT | 02237802 | — |
| CAVERJECT | 02215179 | Cancelled Post Market |
| CAVERJECT | 02215187 | Marketed |
| CAVERJECT | 02237803 | — |
| CAVERJECT KIT | 02237804 | — |
| CAVERJECT KIT | 02215748 | Cancelled Post Market |
| CAVERJECT KIT | 02215756 | Marketed |
| CAVERJECT KIT | 02237805 | — |
| CAVERJECT KIT | 02215721 | Marketed |
Medicinal ingredients
- ALPROSTADIL 6.15 MCG per VIAL
- ALPROSTADIL 11.9 MCG per VIAL
- ALPROSTADIL 23.2 MCG per VIAL
- ALPROSTADIL 46.4 MCG per VIAL
- WATER 99.1 PER